Suggested remit: To appraise the clinical and cost effectiveness of benralizumab within its marketing authorisation for previously treated severe nasal polyps.
 
Status Awaiting development
Decision None selected
Process TA
ID number 1659

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
05 August 2024 Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes.
16 March 2021 The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of benralizumab for previously treated severe nasal polyps. We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal. Following an update from the company that market benralizumab, NICE will not be progressing with the scoping exercise at this stage. The consultation on the draft scope will now close. Please accept our apologies for any inconvenience.

For further information on our processes and methods, please see our CHTE processes and methods manual